您当前的位置：
首页 >
文章列表页 >
Jiedu Tongluo Tiaogan Prescription Protects Pancreatic β Cell by Targeting NLRP3 Inflammasome via TGR5/cAMP Signaling Pathway
更新时间：2024-04-30
|

    • Jiedu Tongluo Tiaogan Prescription Protects Pancreatic β Cell by Targeting NLRP3 Inflammasome via TGR5/cAMP Signaling Pathway

    • “一项关于解毒通络调肝方保护胰岛β细胞的研究取得了重要进展。该研究利用db/db小鼠模型，探讨了该中药方剂如何通过胆汁酸G蛋白偶联受体5（TGR5）/环状磷酸腺苷（cAMP）信号通路靶向NOD样受体蛋白3（NLRP3）炎症小体，从而发挥保护胰岛β细胞的作用。研究结果显示，解毒通络调肝方能够显著降低db/db小鼠的空腹血糖水平，改善口服糖耐量，并降低空腹胰岛素水平。此外，该方剂还能够显著降低小鼠体内的白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）和IL-1β水平，这些都是糖尿病相关炎症的重要指标。在机制方面，解毒通络调肝方能够促进TGR5和cAMP的mRNA上调，并下调NLRP3、凋亡相关斑点样蛋白（ASC）和胱天蛋白酶-1（Caspase-1）的mRNA表达。同时，该方剂还能够增加TGR5蛋白表达，降低NLRP3、Caspase-1和ASC蛋白表达，以及提高cAMP含量。这些结果表明，解毒通络调肝方通过调节TGR5/cAMP信号通路，抑制NLRP3炎症小体的激活，从而保护胰岛β细胞。这项研究为糖尿病治疗提供了新的思路和方法，也为中药方剂在糖尿病治疗中的应用提供了科学依据。未来，我们可以进一步深入研究解毒通络调肝方的具体作用机制，以期为糖尿病的治疗和预防提供更加有效的药物选择。”
    • Chinese Journal of Experimental Traditional Medical Formulae   Vol. 30, Issue 11, Pages: 95-103(2024)

    • DOI：10.13422/j.cnki.syfjx.20232440    

      CLC： R2-0;R33;R289;R587.1

    • Published：05 June 2024，

      Published Online：29 January 2024，

      Received：24 October 2023，

    扫 描 看 全 文

  • ZHANG Qi,XIAO Yang,XU Jinghan,et al.Jiedu Tongluo Tiaogan Prescription Protects Pancreatic β Cell by Targeting NLRP3 Inflammasome via TGR5/cAMP Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(11):95-103. DOI： 10.13422/j.cnki.syfjx.20232440.

  •  
  •  

0

Views

16

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Role of NLRP3 Inflammasome in IgA Nephropathy and Chinese Medicine Intervention： A Review
Relationship Between NLRP3 Inflammasome and Diabetic Cardiomyopathy and Intervention Effect of Traditional Chinese Medicine： A Review
Alcohol Extract of Angelicae Pubescentis Radix Treats Gouty Arthritis Induced by MSU via NLRP3/ASC/Caspase-1 Signaling Pathway
Mechanism of Dendrobium huoshanense Polysaccharide Against Neuroinflammation in Parkinson's Disease Model： Based on NLRP3 Inflammasome

Related Author

ZHOU Li
LIU Huiyang
HUANG Rui
FENG Zhiying
YIN Tiantian
LIU Yongfang
GAO Hong
ZHANG Sai

Related Institution

Graduate School of Jiangxi University of Chinese Medicine
Jiujiang Hospital of Traditional Chinese Medicine Affiliated to Jiangxi University of Chinese Medicine
Hospital of Chengdu University of Traditional Chinese Medicine（TCM）
Key Laboratory of TCM Regulation of Metabolic Diseases in Sichuan Province
Nanjing University of Chinese Medicine
0